Get the Stockscreener App
0.00
100.00%
-100.99
Amedisys Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
See More
Previous Close:
$100.99
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.32B
Revenue:
$2.32B
Net Income/Loss:
$82.93M
P/E Ratio:
0.00
EPS:
2.52
Net Cash Flow:
$203.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$101.02
Amedisys Inc Stock (AMED) Company Profile
Name
Amedisys Inc
Sector
Industry
Phone
(225) 292-2031
Address
3854 AMERICAN WAY, BATON ROUGE, LA
Compare AMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMED
Amedisys Inc
|
0.00 | 3.32B | 2.32B | 82.93M | 203.54M | 2.52 |
|
HCA
Hca Healthcare Inc
|
467.86 | 104.60B | 74.37B | 7.31B | 8.10B | 25.88 |
|
THC
Tenet Healthcare Corp
|
216.17 | 18.59B | 20.69B | 2.40B | 1.55B | 15.62 |
|
FMS
Fresenius Medical Care Ag Adr
|
27.20 | 15.99B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
EHC
Encompass Health Corp
|
127.18 | 12.70B | 5.51B | 494.70M | 386.40M | 4.84 |
|
UHS
Universal Health Services Inc
|
214.03 | 13.41B | 16.08B | 1.20B | 1.06B | 17.82 |
Amedisys Inc Stock (AMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-07-23 | Downgrade | Truist | Buy → Hold |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Mar-13-23 | Initiated | Barclays | Equal Weight |
| Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-02-22 | Downgrade | UBS | Neutral → Sell |
| Jun-29-22 | Initiated | Stifel | Hold |
| Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-01-22 | Upgrade | UBS | Sell → Neutral |
| Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-25-22 | Reiterated | Credit Suisse | Outperform |
| Feb-25-22 | Reiterated | Oppenheimer | Outperform |
| Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-25-22 | Reiterated | Raymond James | Outperform |
| Feb-25-22 | Reiterated | Truist | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | UBS | Sell |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-10-21 | Reiterated | The Benchmark Company | Buy |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-20-20 | Resumed | Barclays | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Buy |
| Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
| May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-17-20 | Initiated | Credit Suisse | Outperform |
| Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-22-19 | Resumed | Stephens | Equal-Weight |
| Sep-17-19 | Initiated | Deutsche Bank | Buy |
| May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-14-18 | Initiated | Barclays | Equal Weight |
| Nov-16-18 | Initiated | UBS | Neutral |
| Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-08-17 | Reiterated | Mizuho | Buy |
| Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
| Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc Stock (AMED) Latest News
Long term hold vs stop loss in Amedisys Inc.Market Volume Report & Smart Money Movement Alerts - newser.com
Why Amedisys Inc. stock attracts global investorsEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Combining price and volume data for Amedisys Inc.Inflation Watch & Reliable Intraday Trade Plans - newser.com
Will a bounce in Amedisys Inc. offer an exitEarnings Summary Report & AI Driven Price Predictions - newser.com
Is Amedisys Inc. stock a defensive play in 2025Weekly Loss Report & AI Based Buy/Sell Signal Reports - newser.com
What Wall Street predicts for Amedisys Inc. stock priceLayoff News & Smart Investment Allocation Insights - newser.com
How hedge fund analytics apply to Amedisys Inc. stockEarnings Beat & Long-Term Growth Stock Strategies - newser.com
Can Amedisys Inc. stock maintain operating marginsOptions Play & Weekly Chart Analysis and Guides - newser.com
Is Amedisys Inc. stock gaining market shareMarket Activity Report & Reliable Entry Point Trade Alerts - newser.com
Why pension funds invest in Amedisys Inc. (ADY) stockTrade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Amedisys Inc Stock (AMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):